Last reviewed · How we verify
Abemaciclib, dexamethasone, ixazomib, pomalidomide
At a glance
| Generic name | Abemaciclib, dexamethasone, ixazomib, pomalidomide |
|---|---|
| Also known as | abemaciclib: Verzenio, LY2835219, ixazomib: Ninlaro, MLN2238, pomalidomide: Pomalyst |
| Sponsor | Multiple Myeloma Research Consortium |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Myeloma-Developing Regimens Using Genomics (MyDRUG) (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: